Sangamo Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program, an investigational epigenetic regul ...

For those with severe RLS, the danger of the rebound effect has prompted a switch in favour of gabapentin (usually prescribed for neuropathic pain) as a “first-line treatment”. This can be combined ...